Do you recommend prostate RT for patients with metastatic (M1) disease?
My short answer to this provocative question is “no, I don’t offer men with M1 disease local radiation unless there’s a palliative need.” Treating the primary in the asymptomatic M1 scenario, whether with RT or with surgery, is a major commitment of time, resources, and risk to the patient. The level of evidence supporting such an expenditure should be strong and one suspects that NCDB or SEER-Medicare are not strong enough sources of data. If NCDB and the like could decide definitely such hard questions, there would be little need for expensive and time-consuming prospective clinical trials. (There’s a reason important prospective trials are published in NEJM and its peers and NCDB studies are usually not.)
Interestingly, there is a prospe...
Join for free or sign in to see the full answer
I’m excited and honored to see a discussion of this manuscript making it all the way to theMednet!
As Dr. @Dr. First Last points out, although the NCDB is an outstanding prospectively-maintained resource, it cannot replace prospective clinical trial data. This is not to say that the trends and outcomes in a database like this are not real, only that level one evidence is clearly necessary for validation. Currently, there are several clinical trials either ongoing or in development to test the role of local prostate therapy (i.e., radiation or surgery) for M1 patients in the randomized setting (NCT00268476; NCT01957436; NCT01751438 ISRCTN 06890529), which we hope will provide the definitive answer to this question. Nevertheless, if an overal...
Join for free or sign in to see the full answer
The JCO paper is interesting but hypothesis generating and so we need to await the results of STAMPEDE before offering RT to men with M1 PC off study with the exception of cases where it is being offered for local control to reduce the risk of obstructive sx's later in a patient with large volume local PC that is not responding well to conventional systemic therapies, such as ADT.
Join for free or sign in to see the full answer
I am a clinician focused on prostate cancer since 1983 -- the so-called "dark ages". I may be the oldest HemOnc MD that continues in practice after all these years. Been there and done that for many aspects of this disease. What is missing in the discussion is a much more intense focus on the staging of this disease and all other malignancies. How can we have a discussion in 2018 about treating the prostate gland in newly diagnosed patients with M1 disease without knowing the extent of M1:
First, the definition of M1 disease:
Stage M1 disease — If the patient’s cancer is classified as M1, then there is clear evidence of prostate cancer somewhere outside the pelvic area. This stage is exactly comparable to stage D2 of the Jewett-Whitmore sys...
Join for free or sign in to see the full answer
The original question referenced STAMPEDE. The results have now been published and showed an OS benefit in a subgroup analysis for patients with "low" metastatic burden (the full trial showed a FFS benefit, but not OS). I offer prostate RT to patients with oligometastatic disease, with this analysis as the rationale.
Join for free or sign in to see the full answer
I have heard some arguments for definitive local treatment (prostatectomy or RT) for patients with oligomets, but I do not agree with this approach since there is no high-quality evidence to justify this approach. I only irradiate bulky primary prostate tumor with obstruction (failure in ADT) or for bleeding or obstruction in patients with mCRPC.
However, I do support a clinical trial to treat patients with bulky prostate cancer and M1 using a modified local therapy such as hypofractionated therapy with reduced BED dose with relatively minimal toxicity. I believe advanced imaging such as mpMRI will help define the bulky disease for local therapy in this type of clinical study, which might be much better than current high-risk definitions.
Join for free or sign in to see the full answer
An intriguing consensus paper recently published showing a majority recommending primary site therapy for synchronous oligometastatic prostate cancer (https://www.ncbi.nlm.nih.gov/pubmed/28655541). Based on the above comments and this paper, I am currently leaning towards recommending radiation to the prostate for a motivated man with long life expectancy and a solitary bone metastasis.
Join for free or sign in to see the full answer
If the Radiation establishment believes in the Abscopal Effect, then now is the time to conduct studies of Radiation as an ablative procedure to be joined with immune therapy to increase the effectiveness of the Abscopal effect. M1 is a good indication and will save money and human suffering for the long run if the treatment is successful. Is it not worthwhile to study?
There is work done with Cryoablation and immunology. Will you submit the patient for Cryoablation and Immunotherapy, especially if the patient already has obstructive symptoms.
What is the opinion of the experts?
Thank you.
Join for free or sign in to see the full answer